High Tech Pharm Co. Ltd (106190) - Total Assets
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) holds total assets worth ₩139.56 Billion KRW (≈ $94.58 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of High Tech Pharm Co. Ltd for net asset value and shareholders' equity analysis.
High Tech Pharm Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's total assets have evolved over time, based on quarterly financial data.
High Tech Pharm Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
High Tech Pharm Co. Ltd's total assets of ₩139.56 Billion consist of 45.9% current assets and 54.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩450.00 | 5.5% |
| Accounts Receivable | ₩20.33 Billion | 14.5% |
| Inventory | ₩34.81 Billion | 24.9% |
| Property, Plant & Equipment | ₩72.00 Billion | 51.4% |
| Intangible Assets | ₩0.00 | 0.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 106190 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: High Tech Pharm Co. Ltd's current assets represent 45.9% of total assets in 2024, a decrease from 66.6% in 2014.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2024, down from 19.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 51.4% of total assets.
High Tech Pharm Co. Ltd Competitors by Total Assets
Key competitors of High Tech Pharm Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
High Tech Pharm Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.56 | 2.82 | 1.50 |
| Quick Ratio | 2.62 | 1.25 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩54.21 Billion | ₩40.44 Billion | ₩13.54 Billion |
High Tech Pharm Co. Ltd - Advanced Valuation Insights
This section examines the relationship between High Tech Pharm Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | ₩140.09 Billion |
| Market Capitalization | $138.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values High Tech Pharm Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: High Tech Pharm Co. Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual total assets of High Tech Pharm Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩140.09 Billion ≈ $94.94 Million |
+3.73% |
| 2023-12-31 | ₩135.06 Billion ≈ $91.53 Million |
+2.16% |
| 2022-12-31 | ₩132.20 Billion ≈ $89.59 Million |
+7.54% |
| 2021-12-31 | ₩122.94 Billion ≈ $83.31 Million |
-4.29% |
| 2020-12-31 | ₩128.45 Billion ≈ $87.05 Million |
-2.49% |
| 2019-12-31 | ₩131.73 Billion ≈ $89.27 Million |
-0.96% |
| 2018-12-31 | ₩133.00 Billion ≈ $90.13 Million |
+11.67% |
| 2017-12-31 | ₩119.10 Billion ≈ $80.71 Million |
+0.67% |
| 2016-12-31 | ₩118.31 Billion ≈ $80.18 Million |
+6.17% |
| 2015-12-31 | ₩111.43 Billion ≈ $75.51 Million |
+4.54% |
| 2014-12-31 | ₩106.60 Billion ≈ $72.24 Million |
-- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.